Everolimus Slows Disease Progression in Some Cases of Advanced Papillary Kidney Cancer

In the 92-patient phase 2 RAPTOR study that tested the effects of everolimus as an initial treatment for advanced papillary kidney cancer, disease was stable after 6 months in 59% of patients according to the per-protocol analysis conducted by local investigators. The central review confirmed this in 35% of patients. The local investigators found that average progression-free survival was 7.8 months, while the central pathology review found it was 3.9 months. At least half of the patients were alive at 20 months. Similar results were seen in the intent-to-treat analysis. The findingswere presented at the 2013 European Cancer Congress.